



23 February 2017
EMA/121408/2017
Human Medicines Evaluation Division

Overview of (invented) names reviewed in February 2017 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 20-23 February 2017

	NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		2017	
	01 Feb 2017		29 March 2017		31 May 2017		06 Jul 2017		20 Sep 2017		22 Nov 2017			
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names	44	26												
Justification for retention of (invented) name *	2	3												

*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.



	NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		NRG meeting		2017	
	01 Feb 2017		29 March 2017		31 May 2017		06 Jul 2017		20 Sep 2017		22 Nov 2017			
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	54	91												
Criterion - Safety concerns														
Similarity with other (invented) name	45	82												
Conveys misleading therapeutic/pharmaceutical connotations	1	0												
Misleading with respect to composition	2	0												
Criterion - INN concerns														
Similarity with INN	4	5												
Inclusion of INN stem	0	3												
Criterion - Other public health concerns														
Unacceptable qualifiers	1	0												
Conveys a promotional message	1	0												
Appears offensive or has an inappropriate connotation	0	0												
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0												
Similarity between name of prodrug and related active substance	0	0												
Others	0	1												

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.